Schwab Charles Investment Management Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,706,832 shares of the biopharmaceutical company’s stock after purchasing an additional 302,787 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.36% of Gilead Sciences worth $333,150,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares during the period. Penserra Capital Management LLC grew its holdings in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the period. Webster Bank N. A. grew its holdings in Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 624 shares during the period. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences during the first quarter worth about $143,000. Finally, Welch Group LLC grew its holdings in Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 252 shares during the period. Hedge funds and other institutional investors own 73.98% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 83.04 on Wednesday. The stock has a market cap of $108.44 billion, a P/E ratio of 9.02 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm has a 50-day moving average price of $81.55 and a 200-day moving average price of $71.93.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.08 earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
WARNING: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://weekherald.com/2017/10/11/gilead-sciences-inc-gild-shares-bought-by-schwab-charles-investment-management-inc.html.
In other news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total value of $5,563,041.38. Following the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 486,819 shares of company stock worth $39,298,919. Corporate insiders own 1.30% of the company’s stock.
Several analysts recently commented on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Jefferies Group LLC reaffirmed a “buy” rating and set a $82.00 target price on shares of Gilead Sciences in a report on Tuesday, July 4th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a report on Monday, July 17th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a report on Wednesday, June 21st. Finally, Deutsche Bank AG started coverage on Gilead Sciences in a report on Friday, June 23rd. They set a “buy” rating and a $79.00 target price on the stock. Twelve analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $85.66.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.